Lipodystrophy due to peptidic growth factors deficiency

disease
On this page

Also known as combined insulin, insulin-like growth factor 1 (IGF1) and epidermal growth factor (EGF) deficiencyHoepffner Dreyer Reimers syndromeHoepffner-Dreyer-Reimers syndromepeptide growth factors deficiencypeptidic growth factors deficiencyWerner-like syndrome due to combined growth factor deficiency

Summary

Lipodystrophy due to peptidic growth factors deficiency (MONDO:0009312) is a disease. A subtype of hereditary lipodystrophy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Prevalence: <1 / 1 000 000 (Worldwide) [Orphanet-validated]
  • Phenotypes (HPO): 28

Clinical features

Epidemiology

Prevalence records

2 prevalence record(s), Orphanet:

TypeClassValueGeographyValidation
Cases/families1WorldwideValidated
Point prevalence<1 / 1 000 000WorldwideValidated

Signs & symptoms

Clinical features (HPO)

28 HPO clinical features (Orphanet curated; top 28 by frequency):

HPO IDTermFrequency
HP:0000160Narrow mouthVery frequent (80-99%)
HP:0000271Abnormality of the faceVery frequent (80-99%)
HP:0000347MicrognathiaVery frequent (80-99%)
HP:0000444Convex nasal ridgeVery frequent (80-99%)
HP:0000767Pectus excavatumVery frequent (80-99%)
HP:0000982Palmoplantar keratodermaVery frequent (80-99%)
HP:0001072Thickened skinVery frequent (80-99%)
HP:0001371Flexion contractureVery frequent (80-99%)
HP:0001387Joint stiffnessVery frequent (80-99%)
HP:0001763Pes planusVery frequent (80-99%)
HP:0001824Weight lossVery frequent (80-99%)
HP:0003758Reduced subcutaneous adipose tissueVery frequent (80-99%)
HP:0004326CachexiaVery frequent (80-99%)
HP:0008065Aplasia/Hypoplasia of the skinVery frequent (80-99%)
HP:0009125LipodystrophyVery frequent (80-99%)
HP:0100578LipoatrophyVery frequent (80-99%)
HP:0100679Lack of skin elasticityVery frequent (80-99%)
HP:0000765Abnormal thorax morphologyFrequent (30-79%)
HP:0001000Abnormality of skin pigmentationFrequent (30-79%)
HP:0001595Abnormality of the hairFrequent (30-79%)
HP:0002216Premature graying of hairFrequent (30-79%)
HP:0002621AtherosclerosisFrequent (30-79%)
HP:0002814Abnormality of the lower limbFrequent (30-79%)
HP:0002817Abnormality of the upper limbFrequent (30-79%)
HP:0003119Abnormal circulating lipid concentrationFrequent (30-79%)
HP:0004349Reduced bone mineral densityFrequent (30-79%)
HP:0010980HyperlipoproteinemiaFrequent (30-79%)
HP:0100651Type I diabetes mellitusFrequent (30-79%)

Identifiers

Disease identifiers

FieldValue
Canonical namelipodystrophy due to peptidic growth factors deficiency
Mondo IDMONDO:0009312
MeSHC565529
OMIM233805
Orphanet1979
ICD-111235390174
SNOMED CT724176001
UMLSC2931279
MedGen419375
GARD0012604
Is cancer (heuristic)no

Also known as: combined insulin, insulin-like growth factor 1 (IGF1) and epidermal growth factor (EGF) deficiency · Hoepffner Dreyer Reimers syndrome · Hoepffner-Dreyer-Reimers syndrome · peptide growth factors deficiency · peptidic growth factors deficiency · Werner-like syndrome due to combined growth factor deficiency

Disease family

This is a subtype of hereditary lipodystrophy. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › metabolic diseaselipodystrophyhereditary lipodystrophylipodystrophy due to peptidic growth factors deficiency

Related subtypes (10): congenital generalized lipodystrophy, Wiedemann-Rautenstrauch syndrome, SHORT syndrome, lipodystrophy-intellectual disability-deafness syndrome, Keppen-Lubinsky syndrome, severe neurodegenerative syndrome with lipodystrophy, lipoatrophy with diabetes, leukomelanodermic papules, liver steatosis, and hypertrophic cardiomyopathy, mandibuloacral dysplasia, Berardinelli-Seip congenital lipodystrophy, familial partial lipodystrophy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.